Medpace Holdings, Inc. (MEDP) EV/Assets Ratio: 5.97x
Is Medpace Holdings, Inc.’s EV/Assets ratio high or low?
Medpace Holdings, Inc.'s EV/Assets ratio of 5.97x is in line with its 5-year average of 5.72x, around the middle of its 5-year range (2.96x–10.56x).
As of Wednesday, June 17, 2026. 25.47% below its 12-month average of 8.01x.
MEDP EV/Assets Ratio Chart
MEDP Average EV/Assets Ratio Chart
MEDP Current vs Average EV/Assets Ratio Chart
MEDP EV/Assets Ratio Metrics
EV/ASSETS RATIO
5.97x
EV/ASSETS RATIO AVG TTM
8.01x
EV/ASSETS RATIO AVG 3Y
6.58x
EV/ASSETS RATIO AVG 5Y
5.33x
EV/ASSETS RATIO AVG 10Y
3.94x
EV/ASSETS RATIO AVG 15Y
N/A
EV/ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-25.47%
CURRENT VS 3Y AVG
-9.29%
CURRENT VS 5Y AVG
+11.91%
CURRENT VS 10Y AVG
+51.55%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | 5.97x | 8.01x | 6.58x | 5.33x |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 1.24x | 1.36x | 1.62x | 1.75x |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 1.89x | 1.75x | 2.55x | 3.74x |
| Solventum Corporation (SOLV)vs › | $13.26B | 1.27x | 1.27x | 1.28x | 1.28x |
| DaVita Inc. (DVA)vs › | $13.46B | 1.54x | 1.38x | 1.35x | 1.31x |
| Revvity, Inc. (RVTY)vs › | $10.91B | 1.12x | 1.11x | 1.18x | 1.38x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.56x | 0.52x | 0.58x | 0.69x |
| Baxter International Inc. (BAX)vs › | $10.19B | 0.92x | 0.91x | 1.05x | 1.32x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 1.91x | 1.84x | 1.98x | 2.08x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 1.54x | 1.51x | 1.59x | 1.95x |
Medpace Holdings, Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Medpace Holdings, Inc. (MEDP)?
- The EV/Assets ratio for MEDP stock is 5.97x.
- Is Medpace Holdings, Inc.'s EV/Assets ratio high or low?
- Medpace Holdings, Inc.'s EV/Assets ratio of 5.97x is in line with its 5-year average of 5.72x, around the middle of its 5-year range (2.96x–10.56x).
- What is the TTM average EV/Assets ratio for Medpace Holdings, Inc. (MEDP)?
- The TTM average EV/Assets ratio for MEDP stock is 8.01x.
- What is the 3Y average EV/Assets ratio for Medpace Holdings, Inc. (MEDP)?
- The 3Y average EV/Assets ratio for MEDP stock is 6.58x.
- What is the 5Y average EV/Assets ratio for Medpace Holdings, Inc. (MEDP)?
- The 5Y average EV/Assets ratio for MEDP stock is 5.33x.
- What is the 10Y average EV/Assets ratio for Medpace Holdings, Inc. (MEDP)?
- The 10Y average EV/Assets ratio for MEDP stock is 3.94x.
Medpace Holdings, Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-17 | 5.97x |
| 2026-06-16 | 6.03x |
| 2026-06-15 | 6.11x |
| 2026-06-12 | 6.11x |
| 2026-06-11 | 6.21x |
| 2026-06-10 | 6.08x |
| 2026-06-09 | 6.10x |
| 2026-06-08 | 5.98x |
| 2026-06-05 | 5.93x |
| 2026-06-04 | 5.99x |
| 2026-06-03 | 5.88x |
| 2026-06-02 | 5.81x |
| 2026-06-01 | 5.89x |
| 2026-05-29 | 5.83x |
| 2026-05-28 | 5.85x |
| 2026-05-27 | 5.57x |
| 2026-05-26 | 5.59x |
| 2026-05-22 | 5.64x |
| 2026-05-21 | 5.60x |
| 2026-05-20 | 5.49x |
| 2026-05-19 | 5.46x |
| 2026-05-18 | 5.47x |
| 2026-05-15 | 5.40x |
| 2026-05-14 | 5.45x |
| 2026-05-13 | 5.51x |
| 2026-05-12 | 5.46x |
| 2026-05-11 | 5.43x |
| 2026-05-08 | 5.52x |
| 2026-05-07 | 5.58x |
| 2026-05-06 | 5.56x |
| 2026-05-05 | 5.60x |
| 2026-05-04 | 5.42x |
| 2026-05-01 | 5.43x |
| 2026-04-30 | 5.44x |
| 2026-04-29 | 5.38x |
| 2026-04-28 | 5.32x |
| 2026-04-27 | 5.48x |
| 2026-04-24 | 5.33x |
| 2026-04-23 | 5.10x |
| 2026-04-22 | 7.33x |
| 2026-04-21 | 7.42x |
| 2026-04-20 | 7.62x |
| 2026-04-17 | 7.51x |
| 2026-04-16 | 7.44x |
| 2026-04-15 | 7.48x |
| 2026-04-14 | 7.50x |
| 2026-04-13 | 7.22x |
| 2026-04-10 | 7.11x |
| 2026-04-09 | 7.23x |
| 2026-04-08 | 7.51x |
| 2026-04-07 | 7.33x |
| 2026-04-06 | 7.15x |
| 2026-04-02 | 7.18x |
| 2026-04-01 | 7.05x |
| 2026-03-31 | 6.92x |
| 2026-03-30 | 6.62x |
| 2026-03-27 | 6.49x |
| 2026-03-26 | 6.72x |
| 2026-03-25 | 6.72x |
| 2026-03-24 | 6.63x |
| 2026-03-23 | 6.57x |
| 2026-03-20 | 6.51x |
| 2026-03-19 | 6.63x |
| 2026-03-18 | 6.54x |
| 2026-03-17 | 6.55x |
| 2026-03-16 | 6.53x |
| 2026-03-13 | 6.48x |
| 2026-03-12 | 6.38x |
| 2026-03-11 | 6.88x |
| 2026-03-10 | 6.72x |
| 2026-03-09 | 6.89x |
| 2026-03-06 | 6.77x |
| 2026-03-05 | 6.76x |
| 2026-03-04 | 6.71x |
| 2026-03-03 | 6.70x |
| 2026-03-02 | 6.58x |
| 2026-02-27 | 6.50x |
| 2026-02-26 | 6.43x |
| 2026-02-25 | 6.30x |
| 2026-02-24 | 6.36x |
| 2026-02-23 | 6.40x |
| 2026-02-20 | 6.53x |
| 2026-02-19 | 6.42x |
| 2026-02-18 | 6.42x |
| 2026-02-17 | 6.15x |
| 2026-02-13 | 6.15x |
| 2026-02-12 | 5.98x |
| 2026-02-11 | 6.09x |
| 2026-02-10 | 6.42x |
| 2026-02-09 | 8.91x |
| 2026-02-06 | 9.11x |
| 2026-02-05 | 9.09x |
| 2026-02-04 | 9.44x |
| 2026-02-03 | 9.55x |
| 2026-02-02 | 9.89x |
| 2026-01-30 | 9.79x |
| 2026-01-29 | 9.97x |
| 2026-01-28 | 10.05x |
| 2026-01-27 | 10.13x |
| 2026-01-26 | 10.12x |
| 2026-01-23 | 9.89x |
| 2026-01-22 | 10.19x |
| 2026-01-21 | 10.44x |
| 2026-01-20 | 10.13x |
| 2026-01-16 | 10.27x |
| 2026-01-15 | 10.39x |
| 2026-01-14 | 10.37x |
| 2026-01-13 | 10.23x |
| 2026-01-12 | 10.07x |
| 2026-01-09 | 10.00x |
| 2026-01-08 | 10.09x |
| 2026-01-07 | 10.31x |
| 2026-01-06 | 10.24x |
| 2026-01-05 | 9.86x |
| 2026-01-02 | 9.60x |
| 2025-12-31 | 9.44x |
| 2025-12-30 | 9.56x |
| 2025-12-29 | 9.58x |
| 2025-12-26 | 9.54x |
| 2025-12-24 | 9.61x |
| 2025-12-23 | 9.57x |
| 2025-12-22 | 9.61x |
| 2025-12-19 | 9.55x |
| 2025-12-18 | 9.41x |
| 2025-12-17 | 9.36x |
| 2025-12-16 | 9.39x |
| 2025-12-15 | 9.40x |
| 2025-12-12 | 9.37x |
| 2025-12-11 | 9.51x |
| 2025-12-10 | 9.42x |
| 2025-12-09 | 9.14x |
| 2025-12-08 | 9.23x |
| 2025-12-05 | 9.21x |
| 2025-12-04 | 9.15x |
| 2025-12-03 | 9.69x |
| 2025-12-02 | 9.81x |
| 2025-12-01 | 9.88x |
| 2025-11-28 | 9.96x |
| 2025-11-26 | 10.20x |
| 2025-11-25 | 10.29x |
| 2025-11-24 | 10.40x |
| 2025-11-21 | 9.95x |
| 2025-11-20 | 9.85x |
| 2025-11-19 | 9.96x |
| 2025-11-18 | 9.92x |
| 2025-11-17 | 9.85x |
| 2025-11-14 | 9.92x |
| 2025-11-13 | 9.94x |
| 2025-11-12 | 10.05x |
| 2025-11-11 | 10.14x |
| 2025-11-10 | 10.10x |
| 2025-11-07 | 9.90x |
| 2025-11-06 | 9.96x |
| 2025-11-05 | 10.07x |
| 2025-11-04 | 10.00x |
| 2025-11-03 | 9.99x |
| 2025-10-31 | 9.83x |
| 2025-10-30 | 9.76x |
| 2025-10-29 | 9.83x |
| 2025-10-28 | 9.76x |
| 2025-10-27 | 10.03x |
| 2025-10-24 | 10.18x |
| 2025-10-23 | 10.03x |
| 2025-10-22 | 10.56x |
| 2025-10-21 | 10.54x |
| 2025-10-20 | 10.51x |
| 2025-10-17 | 10.20x |
| 2025-10-16 | 10.07x |
| 2025-10-15 | 9.94x |
| 2025-10-14 | 9.99x |
| 2025-10-13 | 10.19x |
| 2025-10-10 | 9.69x |
| 2025-10-09 | 10.02x |
| 2025-10-08 | 10.26x |
| 2025-10-07 | 10.27x |
| 2025-10-06 | 10.24x |
| 2025-10-03 | 10.29x |
| 2025-10-02 | 10.36x |
| 2025-10-01 | 10.50x |
| 2025-09-30 | 9.93x |
| 2025-09-29 | 9.68x |
| 2025-09-26 | 9.60x |
| 2025-09-25 | 9.43x |
| 2025-09-24 | 9.61x |
| 2025-09-23 | 9.59x |
| 2025-09-22 | 9.63x |
| 2025-09-19 | 9.64x |
| 2025-09-18 | 9.70x |
| 2025-09-17 | 9.62x |
| 2025-09-16 | 9.49x |
| 2025-09-15 | 9.59x |
| 2025-09-12 | 9.48x |
| 2025-09-11 | 9.62x |
| 2025-09-10 | 9.21x |
| 2025-09-09 | 9.39x |
| 2025-09-08 | 9.51x |
| 2025-09-05 | 9.41x |
| 2025-09-04 | 9.32x |
| 2025-09-03 | 9.30x |
| 2025-09-02 | 9.15x |
| 2025-08-29 | 9.19x |
| 2025-08-28 | 9.14x |
| 2025-08-27 | 9.15x |
| 2025-08-26 | 9.07x |
| 2025-08-25 | 9.03x |
| 2025-08-22 | 8.96x |
| 2025-08-21 | 8.77x |
| 2025-08-20 | 9.00x |
| 2025-08-19 | 8.94x |
| 2025-08-18 | 8.95x |
| 2025-08-15 | 8.85x |
| 2025-08-14 | 8.87x |
| 2025-08-13 | 9.05x |
| 2025-08-12 | 8.88x |
| 2025-08-11 | 8.70x |
| 2025-08-08 | 8.40x |
| 2025-08-07 | 8.30x |
| 2025-08-06 | 8.33x |
| 2025-08-05 | 8.44x |
| 2025-08-04 | 8.37x |
| 2025-08-01 | 8.19x |
| 2025-07-31 | 8.27x |
| 2025-07-30 | 8.47x |
| 2025-07-29 | 8.66x |
| 2025-07-28 | 8.76x |
| 2025-07-25 | 8.65x |
| 2025-07-24 | 8.81x |
| 2025-07-23 | 8.46x |
| 2025-07-22 | 9.23x |
| 2025-07-21 | 4.91x |
| 2025-07-18 | 4.96x |
| 2025-07-17 | 5.08x |
| 2025-07-16 | 5.01x |
| 2025-07-15 | 4.98x |
| 2025-07-14 | 5.10x |
| 2025-07-11 | 5.15x |
| 2025-07-10 | 5.23x |
| 2025-07-09 | 5.11x |
| 2025-07-08 | 5.14x |
| 2025-07-07 | 5.08x |
| 2025-07-03 | 5.12x |
| 2025-07-02 | 5.19x |
| 2025-07-01 | 5.11x |
| 2025-06-30 | 4.99x |
| 2025-06-27 | 4.94x |
| 2025-06-26 | 4.88x |
| 2025-06-25 | 4.95x |
| 2025-06-24 | 5.02x |
| 2025-06-23 | 4.91x |
| 2025-06-20 | 4.92x |
| 2025-06-18 | 4.81x |
| 2025-06-17 | 4.73x |
| 2025-06-16 | 4.78x |
| 2025-06-13 | 4.74x |
| 2025-06-12 | 4.83x |
| 2025-06-11 | 4.80x |
| 2025-06-10 | 4.86x |
| 2025-06-09 | 4.74x |
| 2025-06-06 | 4.71x |
| 2025-06-05 | 4.66x |
Showing the most recent 260 of 2,476 data points. The chart above shows the full history.
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle